Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 372 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Urothelial Bladder Cancer Clear all

Conditions: Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions: Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Bladder Cancer, Skin Cancers, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Urothelial Carcinoma
Interventions: DN24-02, Standard of Care; Biological · Other
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 60
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more

Conditions: Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Bladder EpiCheck; Diagnostic Test
Lead sponsor: Nucleix Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
Interventions: Cisplatin, Gemcitabine, ALT-801; Drug · Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 16
States / cities: Tucson, Arizona • Orlando, Florida • Stuart, Florida + 13 more

Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 448
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more

Conditions: Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation; Genetic · Radiation
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 10
States / cities: Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more

Conditions: Solid Tumor, Adult
Interventions: TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6; Combination Product
Lead sponsor: Trishula Therapeutics, Inc.; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more

Conditions: Bladder Cancer
Interventions: therapeutic conventional surgery, therapeutic standard lymphadenectomy, therapeutic extended lymphadenectomy; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 29
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more

Conditions: Bladder Cancer
Interventions: gemcitabine, cisplatin, sargramostim, filgrastim; Drug
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Louisville, Kentucky • Omaha, Nebraska • Hawthorne, New York + 1 more

Conditions: Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Sapanisertib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 20
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 12 more

Conditions: Hematuria - Cause Not Known
Interventions: Cxbladder Triage Plus; Diagnostic Test
Lead sponsor: Pacific Edge Limited; Industry
Eligibility: 18 Years to 88 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more

Conditions: Bladder Cancer
Interventions: filgrastim, cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine sulfate, conventional surgery; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Cancer, Bladder Cancer
Interventions: Lapatinib and Paclitaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions: B-701, Pembrolizumab; Drug
Lead sponsor: Rainier Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Greenbrae, California • Fort Wayne, Indiana • Louisville, Kentucky + 5 more

Conditions: Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
Interventions: nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 2 more

Conditions: Bladder Cancer, Urothelial Carcinoma, Hematuria, Smoking Cessation
Interventions: Urinalysis; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions: NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more

Conditions: Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Duarte, California • Indianapolis, Indiana • Albuquerque, New Mexico + 1 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Enfortumab vedotin, Pembrolizumab; Drug
Lead sponsor: Matthew Galsky; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Duarte, California • Indianapolis, Indiana • New York, New York + 1 more

Conditions: Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions: BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 174
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more

Conditions: Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
Interventions: Enfortumab vedotin, Pembrolizumab, Cisplatin, Gemcitabine, Fluorouracil, Mitomycin c, Radical cystectomy, Radiation therapy; Drug · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Invasive Bladder Cancer
Interventions: HIPEC; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Ureteral Cancer, Urothelial Cancer, Bladder Cancer
Interventions: Enfortumab Vedotin, Docetaxel, Vinflunine, Paclitaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 25
States / cities: Orange, California • Sacramento, California • Whittier, California + 21 more

Search by objective public record fields.

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

MAGE-A4ᶜ¹º³²T for Multi-Tumor

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer

Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer

A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Bladder Cancer Screening Trial

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Pembrolizumab in Muscle-invasive Bladder Cancer

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)